EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
(NASDAQ: EYPT) Delayed: 3.85 -0.14 (3.51%)
Previous Close $3.99    52 Week High $ 
Open $3.95    52 Week Low $ 
Day High $4.06    P/E N/A 
Day Low $3.77    EPS $ 
Volume 7,264,455